Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spain's 29 regional breast cancer groups tighten awareness efforts:

This article was originally published in Clinica

Executive Summary

Throughout October, Spain's 29 regional breast cancer federations are conducting campaigns to raise awareness of the disease and its early diagnosis and management. One such event was the VI breast cancer conference, held yesterday in Ciudad Real, hosted by the Castilla-La Mancha regional association (AMUMA). Such initiatives, co-ordinated by the overarching FECMA federation, are helping to steer significant changes in regional policy on screening. Cancer care has gained significant political weight in Spain's public healthcare agenda: in recent months, a number of regions have extended or considered extending the age range of their programme (see Clinica No 1269, p 4). Some 17,000 cases of breast cancer are diagnosed in Spain annually, according to FECMA.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel